On March 23, 2021 TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., reported that a poster highlighting the pivotal Phase 2 ENVASARC clinical trial will be presented at the upcoming American Association for Cancer Research (AACR) (Free AACR Whitepaper) virtual meeting, being held April 10-15, 2021 (Press release, Tracon Pharmaceuticals, MAR 23, 2021, View Source [SID1234577038]). The poster will include an oral review by Sandra D’Angelo, M.D., from Memorial Sloan Kettering Cancer Center.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Poster Title: ENVASARC: A Pivotal Trial of Envafolimab, and Envafolimab in Combination with Ipilimumab, in Patients with Advanced or Metastatic Undifferentiated Pleomorphic Sarcoma or Myxofibrosarcoma who have Progressed on Prior Chemotherapy
Abstract Link: View Source!/9325/presentation/4849
Session Category: Phase II Clinical Trials in Progress
Date Available: April 10, 2021
Poster Number: CT239
The poster will be available on the publications page of the company’s website following presentation.